Health Condition 1: L988- Other specified disorders of the skin and subcutaneous tissue
Conditions
Interventions
None listed
Sponsors
Shree Swaminarayan Ayurvedic College
Eligibility
Inclusion criteria
Inclusion criteria: Patients clinically diagnosed with Padadari with typical symptoms for greater than equal to 1 month Age Group 18 to 60 years as already specified Gender Both male and female subjects will be included
Exclusion criteria
Exclusion criteria: Pre existing Skin Disease Psoriasis eczema fungal infections eg Tinea pedis allergic skin conditions or any other dermatological conditions affecting the feet that might confound the diagnosis or assessment of Padadari Systemic Diseases Affecting Healing Uncontrolled Diabetes Mellitus Patients with Random Blood Sugar RBS value more than 250 mg per dL will be excluded Diabetic foot as already specified peripheral vascular disease severe nutritional disorders or any other systemic disease known to significantly impair wound healing or skin integrity Contraindications to Siravedhana This is critical for patient safety in Group A Patients on anticoagulant therapy eg Warfarin Heparin or antiplatelet agents eg Aspirin Clopidogrel that cannot be safely discontinued Active local infection inflammation or cellulitis at the proposed site of Siravedhana Pregnancy and Lactation such as Pregnant or lactating women should always be excluded in drug trials unless specifically designed for this population Substance Abuse like History of drug or alcohol abuse that might affect compliance or general health Mental or Cognitive Impairment like Patients with any psychiatric disorder or cognitive impairment that would affect their ability to give informed consent or comply with the study protocol Participation in Other Trials as Patients currently participating in another clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in the depth and number of heel fissures, and improvement in skin integrity,Cracks associated with pain,Itching sensationTimepoint: Baseline and day 21 | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in associated discomfort and quality of life parametersTimepoint: Baseline and day 21 | — |
Countries
India
Contacts
Public ContactDR DARSHANA RAMOLE
Shree Swaminarayan Ayurvedic College Kalol
Outcome results
None listed